Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 4:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 36 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Motexafin gadolinium Clear all
Completed Phase 1 Interventional

Motexafin Gadolinium Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma

NCT00003909
View directory record Official record
Conditions
Untreated Childhood Brain Stem Glioma
Interventions
motexafin gadolinium, radiation therapy, pharmacological study
Drug · Radiation · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Up to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Sep 11, 2026, 4:17 AM EDT
Not listed Phase 2 Interventional

Sunitinib Before and After Surgery in Treating Patients With Stage IV Kidney Cancer

NCT00717587
View directory record Official record
Conditions
Kidney Cancer
Interventions
motexafin gadolinium, sunitinib malate, comparative genomic hybridization, gene expression analysis, mutation analysis, polymorphism analysis, immunohistochemistry staining method, iodine I-124 girentuximab, laboratory biomarker analysis, pharmacological study, adjuvant therapy, neoadjuvant therapy, therapeutic conventional surgery
Drug · Genetic · Other + 1 more
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Sep 11, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional

Study of Motexafin Gadolinium With Whole Brain Radiation Therapy Followed by Stereotactic Radiosurgery Boost in the Treatment of Patients With Brain Metastases

NCT00121420
View directory record Official record
Conditions
Neoplasm Metastasis, Brain Neoplasms
Interventions
Motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
9
States / cities
Phoenix, Arizona • Aurora, Colorado • Cleveland, Ohio + 6 more
Source: ClinicalTrials.gov public record
Updated May 8, 2014 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 1 Interventional

Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme

NCT00004262
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
conventional surgery, 3-dimensional conformal radiation therapy, stereotactic radiosurgery, motexafin gadolinium, magnetic resonance imaging, spectroscopy
Procedure · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 3, 2013 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 2 Interventional

A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma

NCT00096837
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 7, 2006 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 3 Interventional

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Brain Metastases

NCT00003563
View directory record Official record
Conditions
Metastatic Cancer
Interventions
WBRT, MGd
Radiation · Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2005
U.S. locations
31
States / cities
Greenbrae, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 11, 2026, 4:17 AM EDT
Terminated Phase 1 Interventional

Motexafin Gadolinium With Chemotherapy and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer

NCT00080028
View directory record Official record
Conditions
Head and Neck Cancer, Oropharynx Cancer, Larynx Cancer, Hypopharynx Cancer
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
2
States / cities
Durham, North Carolina • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Sep 11, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional

Trial of Motexafin Gadolinium and Pemetrexed (Alimta®) for Second Line Treatment in Patients With Non-Small Cell Lung Cancer

NCT00365183
View directory record Official record
Conditions
Non-Small Cell Lung Carcinoma
Interventions
Motexafin gadolinium and pemetrexed
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Huntington Beach, California • Long Beach, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2013 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 2 Interventional

Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma

NCT00086034
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin's Lymphoma
Interventions
Motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
7
States / cities
San Diego, California • Stanford, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated May 14, 2007 · Synced Sep 11, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional

Study of the Effect on Non-small Cell Lung Cancer of the Investigational Drug Motexafin Gadolinium When Used in Combination With Docetaxel (Taxotere)

NCT00373204
View directory record Official record
Conditions
Lung Cancer
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
7
States / cities
La Verne, California • Rochester, New York • Canton, Ohio + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium Plus Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00003409
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
motexafin gadolinium, radiation therapy
Drug · Radiation
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
2
States / cities
Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Feb 8, 2009 · Synced Sep 11, 2026, 4:17 AM EDT
Not listed Not applicable Interventional

Studying Repeated DCE-MRI and DWI in Patients Diagnosed With Prostate Cancer

NCT01562223
View directory record Official record
Conditions
Prostate Cancer
Interventions
motexafin gadolinium
Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 17, 2021 · Synced Sep 11, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional

A Study of Motexafin Gadolinium for the Treatment of Chronic Lymphocytic Leukemia (CLL)

NCT00076401
View directory record Official record
Conditions
Leukemia, Leukemia, Lymphocytic, Chronic
Interventions
Motexafin gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 25, 2014 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 2 Interventional

Motexafin Gadolinium Plus Radiation Therapy to the Brain in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

NCT00022256
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
motexafin gadolinium, radiation therapy
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 1 Interventional

Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors

NCT00080041
View directory record Official record
Conditions
Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms
Interventions
Motexafin Gadolinium Injection
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2007 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 1 Interventional

Motexafin Gadolinium With MRI-Guided Surgery in Treating Patients With High-Grade Gliomas

NCT00003410
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
motexafin gadolinium, magnetic resonance imaging, surgical procedure
Drug · Procedure
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2013 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 3 Interventional

Study of Neurologic Progression With Motexafin Gadolinium and Radiation Therapy (SMART)

NCT00054795
View directory record Official record
Conditions
Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Metastases, Neoplasm
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
44
States / cities
Phoenix, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated May 7, 2007 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 1 Interventional

Study of Motexafin Gadolinium and Docetaxel for Advanced Cancer

NCT00120939
View directory record Official record
Conditions
Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Lung Neoplasms, Gastrointestinal Neoplasms
Interventions
Motexafin Gadolinium
Drug
Lead sponsor
Pharmacyclics LLC.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 2, 2009 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

NCT00305864
View directory record Official record
Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Motexafin Gadolinium, Temozolomide
Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
106
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2018 · Synced Sep 11, 2026, 4:17 AM EDT
Not listed Not applicable Interventional

Contrast-Enhanced CT and MRI in Diagnosing and Staging Liver Cancer Using UNOS Policy

NCT01082224
View directory record Official record
Conditions
Liver Cancer
Interventions
iodinated contrast dye, motexafin gadolinium, Eovist-enhanced MRI
Drug · Other
Lead sponsor
American College of Radiology Imaging Network
Network
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
9
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 11, 2026, 4:17 AM EDT
Completed Phase 1 Interventional

Radiation Therapy Plus Gadolinium Texaphyrin in Treating Patients With Cancer of the Pancreas That Cannot Be Removed by Surgery

NCT00003798
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
motexafin gadolinium, radiation therapy
Drug · Radiation
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 13, 2012 · Synced Sep 11, 2026, 4:17 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of Zevalin Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab-Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

NCT01549886
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma
Interventions
Y-90-Zevalin, Moxtezafin Gadolinium, Rituximab
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
9
States / cities
Berkeley, California • Burbank, California • Daytona Beach, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2021 · Synced Sep 11, 2026, 4:17 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Redox Regulation in Patients With Relapsed or Refractory CD20+ NHL

NCT00089284
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma (NHL)
Interventions
Rituxan, motexafin gadolinium, 111Indium-Zevalin and 90Yttrium-Zevalin
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
2
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Sep 11, 2026, 4:17 AM EDT
Approved For Marketing No phase listed Expanded access

18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer

NCT04809584
View directory record Official record
Conditions
Prostate Cancer
Interventions
F18-DCFPyL, Gadolinium, Positron emission tomography (PET)/Magnetic Resonance Imaging (MRI) Scan
Drug · Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Male only
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Sep 11, 2026, 4:17 AM EDT